Episode 2353
2353: Poolbeg Pharma Secures First Oncology Patent for POLB 001
The Vox Markets Podcast · Vox Markets Podcast
March 31, 20267m 4s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Poolbeg Pharma announces its first granted patent for POLB 001 in cancer immunotherapy-induced CRS, strengthening its global IP position. The milestone supports future partnering opportunities as the company advances toward key clinical data in 2026.